Sign in to view content

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Vrinda S. Hershberger, MD, PhD

Video
Published 2021

Related

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Wet AMD
Jared Watson
Paul Yates, MD, PhD
Retina Image Bank: Images of the Week
2015
Association Between Provider Anti-VEGF Injection Rates and Visual Outcome In Eyes With Neovascular Age-Related Macular Degeneration
Michael M. Lai, MD, PhD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more